ELECTRONIC POSTER - ismrm

14:00 4287. Differentiation Between Glioblastomas, Brain Metastases and Primary Cerebral
Lymphomas Using Diffusion and Perfusion Weighted Imaging
Sumei Wang 1 , Sungheon Kim 2 , Sanjeev Chawla 1 , Ronald L. Wolf 1 , David Knipp 1 , Arastoo
Vossough 1 , Donald M. O’Rourke 3 , Kevin D. Judy 3 , Elias R. Melhem 1 , Harish Poptani 1
1 Radiology, University of Pennsylvania, Philadelphia, PA, United States; 2 Radiology, New York University
School of Medicine, New York, NY, United States; 3 Neurosurgery, University of Pennsylvania, Philadelphia,
PA, United States
Twenty-six glioblastomas, 25 brain metastases and 16 cerebral lymphomas underwent DTI and DSC studies. FA, ADC, CL, CP, CS
and rCBV were measured from the enhancing part of the tumor. Elevated FA, CL, CP and decreased CS were observed in
glioblastomas compared with both metastases and lymphomas, whereas ADC and rCBV values from glioblastomas were significantly
higher than lymphomas. FA and ADC was the best predictor for differentiation of glioblastomas from non-glioblastomas, whereas
ADC, CS and rCBV were the best model for distinguishing lymphomas from metastases. Our study indicates that DTI metrics along
with rCBV measurement may be helpful in tumor classification.
14:30 4288. Initial RCBV Predicts Response to Bevacizumab in Patients with High-Grade
Gliomas
Kathleen M. Schmainda 1,2 , Devyani Bedekar 1,2 , Scott D. Rand 1,2 , Jennifer Connelly, 23 ,
Mark Malkin, 23
1 Radiology, Medical College of Wisconsin, Milwaukee, WI, United States; 2 Translational Brain Tumor
Research Program, Medical College of Wisconsin, Milwaukee, WI, United States; 3 Neurology, Medical College
of Wisconsin, Milwaukee, WI, United States
The prognosis for patients diagnosed with brain tumors has been dismal. Now there is hope with improved time to progression and
survival noted for patients treated with anti-angiogenic drugs such as bevacizumab. Yet, many questions remain regarding the
appropriate selection of patients most likely to respond. These questions are important from both a clinical and economic perspective
and therefore speak to the need for ways to efficiently and reliably predict response. Here we demonstrate the potential of DSCmeasures
of rCBV, obtained just prior to treatment with bevacizumab, to predict outcomes in patients with both new and recurrent
GBM.
15:00 4289. Using Cerebrovascular Response to Hyperoxia for Assessing Treatment Resonse in
Glioblastoma
Heisoog Kim 1,2 , Ciprian Catana 1 , Grace Kim 1 , Ovidiu C. Andronesi 1 , Dominique L.
Jennings 1 , Divya S. Bolar 1,3 , Elizabeth R. Gerstner 4 , Tracy T. Batchelor 4 , Rakesh K.
Jain 5 , Alma Gregory Sorensen 1
1 A.A.Martinos center, Massachusetts General Hospotal, Charlestown, MA, United States; 2 NSE/HST,
Massachusetts Institute of Technology, Cambridge, MA, United States; 3 EECS/HST, Massachusetts Institute of
Technology, Cambridge, MA, United States; 4 Neurology, Massachusetts General Hospotal, Boston, MA,
United States; 5 Radiology, Massachusetts General Hospotal, Boston, MA, United States
This study quantitatively investigated BOLD responses to pure oxygen in glioblastoma (GBM) throughout the course of the treatment
with chemoradiation and an anti-angiogenic drug. BOLD signal changes dropped significantly at the beginning of the treatment in
tumor and gradually recovered afterwards. Conversely, in contralateral normal tissue a slight increase was observed at the early time
points. Interestingly, no difference was observed between values in both regions after 35 days. Our preliminary findings suggest that
assessing the oxygenation status before and after treatment might be useful for both prognostic and diagnostic assessment in GBM
patients.
Thursday 13:30-15:30 Computer 74
13:30 4290. Correlation Between Imaging Findings of Magnetic Susceptibility Weighted Images
and MIB-1 Labeling Index.
Kazuchika Hagiwara 1 , Akira Kunimatsu 1 , Wataru Gonoi 1 , Harushi Mori 1 , Osamu Abe 1 ,
Kuni Ohtomo 1 , Hiroyuki Kabasawa 2
1 Radiology, Tokyo University Hospital, Bunkyouku, Tokyoto, Japan; 2 GE Healthcare Japan
The purpose of this study was to examine with or without of association between findings in phase sensitive imaging (PSI) that is a
susceptibility weighted imaging method and MIB-1 Labeling Index (LI) that is a marker of malignancy of human brain tumors. Forty
brain tumors were studied with 3 T MRI and properties of intratumoral dark spots in PSI were graded on scale of 1 to 4 subjectively
depending on area proportions of dark spots within tumors. Statistically significant difference of MIB-1 LI was found between low
and high grade tumor groups.